Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01896999 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

StatusActive, Not Recruiting
PhasePhase 1/2
Started2014-03-07
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Dec 31, 2026 → Jun 30, 2027
See other at-risk trials from National Cancer Institute (NCI)

Amendment history

The 50 most recent of 738 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

2026-09-30
Primary completion pushed: 2026-12-31 → 2027-06-30
Completion pushed: 2026-12-31 → 2027-06-30
2026-08-18
Study Status v737
Re-verified, no change to tracked fields
2026-08-08
Study Status, Outcome Measures, Eligibility, Contacts/Locations v736
Study sites480→479
Eligibility criteria-47 characters
[...] patient of childbearing potential is anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the fo [...] f childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the f [...] GFR) >= 70 mL/min/1.73 m^2 or serum creatinine based on age/gendersex as follows: Age: maximum serum creatinine (mg/dL) < 13 year [...]
2026-07-01
Study Status, Contacts/Locations v735
Study sites480 entries, revised
FlagetCommonSpirit Memorial Hospital Saint Joseph Hospital East- Bardstown CommonSpirit Saint Joseph Medical Center - East Lexington CommonSpirit Saint Joseph Hospital London
2026-06-12
Study Status, Contacts/Locations v734
Study sites481→480
Show 46 earlier versions
2026-05-28
Study Status, Contacts/Locations v733
Study sites481 entries, revised
CommonSpirit Saint Anthony Hospital Saint Michael Cancer Center Saint Joseph Medical Center Hematology and Oncology - Silverdale
2026-05-12
Study Status, Arms and Interventions v732
Re-verified, no change to tracked fields
2026-04-30
Study Status, Contacts/Locations v731
Study sites482→481
2026-04-09
36 amendments v695-v730
36 re-verifications since 2026-02-19, no change to tracked fields
2025-11-14
Study Status, Contacts/Locations v694
Study sites482 entries, revised
Banner McKeeNorth Colorado Medical Center - Loveland Campus
2025-10-28
Study Status, Contacts/Locations v693
Study sites484→482
2025-10-17
Study Status, Contacts/Locations v692
Study sites484 entries, revised
Rush UniversityMD MedicalAnderson Cancer Center
2025-09-19
Study Status, Contacts/Locations v691
Study sites484 entries, revised
GenesisCareOncology USALas Vegas - Henderson GenesisCareOncology USALas Vegas - Vegas Tenaya
2025-09-02
2 amendments v689-v690
2 re-verifications since 2025-08-19, no change to tracked fields
2025-08-12
Study Status, Contacts/Locations v688
Study sites484 entries, revised
SouthwestCommonSpirit OncologyCancer PCCenter Mercy
This phase I/II trial studies the side effects and best dose of ipilimumab and nivolumab when given together with brentuximab vedotin, and how well they work in treating patients with Hodgkin lymphoma that has returned after a period of improvement (recurrent) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. It is not known whether giving brentuximab vedotin and nivolumab with or without ipilimumab may kill more cancer cells.
Trial Details
NCT Number NCT01896999
Lead Sponsor National Cancer Institute (NCI)
Conditions Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Enrollment 146 participants
Start Date 2014-03-07
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-29